BIOMARKER:

EGFR positive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

C2 | Resistant

C3 | Resistant

D | Resistant

Show legend

Include preclinical:

Drug categories

EGFR

Tyrosine Kinase Inhibitors

Chemotherapy

Non Small Cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Nasopharyngeal Carcinoma

Solid Tumor

Lung Cancer

Breast Cancer

Hepatocellular Cancer

cetuximab

EGFR positive|Solid Tumor|cetuximab

EGFR positive|Lung Cancer|cetuximab

EGFR positive|Breast Cancer|cetuximab

EGFR positive|Hepatocellular Cancer|cetuximab

MRG003

EGFR positive|Squamous Cell Carcinoma of Head and Neck|MRG003

EGFR positive|Nasopharyngeal Carcinoma|MRG003

aumolertinib

EGFR positive|Non Small Cell Lung Cancer|aumolertinib

gefitinib + anlotinib

EGFR positive|Non Small Cell Lung Cancer|gefitinib + anlotinib